The ACVIM Forum is an annual event arranged by the American College of Veterinary Internal Medicine that this year is held on June 4-7 in Nashville, TN, U.S. There will be oral abstracts and symposiums related to Paccal Vet-CA1 and Oasmia’s patented excipient XR-17. For more information about ACVIM, please go to www.acvim.org.
Paccal Vet-CA1 received earlier this year conditional approval by the U.S. Food and Drug Administration (FDA) for the treatment of canine mammary carcinoma and squamous cell carcinoma. It is the first veterinary drug to utilize paclitaxel, one of the most frequently used chemotherapeutics for the treatment of a wide range of cancers in humans for the past 20 years.
Abbott’s Animal Health division has exclusive worldwide distribution rights to Paccal Vet-CA1 excluding Japan, Russia and the Commonwealth of Independent States (CIS).
Paccal Vet-CA1 is manufactured and supplied by Oasmia.
For more information, please contact:
Mikael Widell, Vice President Communications
Mobile: +46 70 311 99 60
E-mail: mikael.widell@oasmia.com
Notes to Editors:
About Paccal Vet®-CA1 (paclitaxel for injection)
Paccal Vet-CA1 is a paclitaxel cancer treatment developed especially for dogs. It is a novel formulation containing paclitaxel, one of the most frequently used human chemotherapeutic agents. Paccal Vet-CA1 is a novel nanoparticle formulation composed of Oasmia Pharmaceutical’s patented excipient XR-17 that can be used to improve the solubility of substances like paclitaxel in suitable aqueous solvents. Two prospective, blinded, randomized trials to obtain full regulatory approvals in the U.S. and Europe are soon to be initiated.
In the United States, Paccal Vet-CA1 is indicated for the treatment of resectable and non-resectable squamous cell carcinoma (a type of skin cancer) in dogs that have not received previous chemotherapy or radiotherapy, and for the treatment of non-resectable stage III, IV or V mammary carcinoma (mammary cancer) in dogs that have not received previous chemotherapy or radiotherapy. These indications are conditionally approved pending a full demonstration of effectiveness.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).